MARKET

BEIGF

BEIGF

Beigene
OTCPK
28.45
NaN%
Closed 09:30 12/26 EST
OPEN
--
PREV CLOSE
28.45
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
28.45
52 WEEK LOW
14.40
MARKET CAP
40.56B
P/E (TTM)
-1012.4555
1D
5D
1M
3M
1Y
5Y
1D
Tracking Baker Brothers Portfolio - Q3 2025 Update
Seeking Alpha · 12/16 14:19
Zymeworks shifts to a royalty-driven business model
Seeking Alpha · 11/18 17:24
Jazz, Zymeworks’ Ziihera trial shows significant PFS improvement, shares rally
Seeking Alpha · 11/17 12:13
Saudi sovereign wealth fund cuts holdings of U.S. stocks
Seeking Alpha · 11/16 14:16
BeOne Medicines outlines $5.1B–$5.3B 2025 revenue target amid BRUKINSA momentum and expanding pipeline
Seeking Alpha · 11/06 20:17
BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline
Seeking Alpha · 10/14 20:24
BeOne Medicines' sonrotoclax gets FDA breakthrough therapy status
Seeking Alpha · 10/13 13:08
Tracking Baker Brothers Portfolio - Q2 2025 Update
Seeking Alpha · 09/16 00:21
More
About BEIGF
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.

Webull offers BeOne Medicines AG stock information, including OTCPK: BEIGF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEIGF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEIGF stock methods without spending real money on the virtual paper trading platform.